Radiation Treatment for Ewing Family of Tumors in Adults: The University of Florida Experience

Shi, Wenyin; Indelicato, Daniel J.; Keole, Sameer R.; Morris, Christopher G.; Scarborough, Mark T.; Gibbs, Parker; Zlotecki, Robert A.

doi:10.1016/j.ijrobp.2008.02.071

Cited by 15 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median number of chemotherapy cycles in group A was 6 (range 3-26), including for recurrent disease. In group B, the median number of chemotherapy cycles was 9 (range [2][3][4][5][6][7][8][9][10][11][12][13][14]. Similar results were reported by others [17,25].…”

Section: Discussionsupporting

confidence: 79%

“…Moreover, in cases of disseminated multifocal ESFT, patients may benefit from intensive multimodal treatment that includes high-dose chemotherapy (HDCT) and autologous stem cell transplantation (SCT) [5]. This multimodality treatment has resulted in a remarkable improvement in overall 5-year survival and has been implemented as the treatment approach in the adult population with satisfying results [6][7][8][9][10][11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of adult patients with Ewing’s sarcoma: compliance with chemotherapy protocols & toxicity

2010

View full text Add to dashboard Cite

Data on treatment outcome of adult patients with Ewing's sarcoma family of tumors (ESFT) are scarce. In some reports, adults with ESFT were found to have a worse outcome than children. The aim of this study was to assess compliance with chemotherapy protocols and toxicity and to compare two adult age groups. A retrospective analysis of clinical records of adult patients (≥ 21 years) treated at our center for ESFT from January 2000 to June 2010 was performed. Data recorded included demographics, clinical features, and outcomes. Patients were divided into two groups: ≥ 40 years (Group A) and < 40 years (Group B). Twenty-two patients were included in the analysis, nine in Group A and 13 in Group B. Median age was 54 years in group A and 29 years in group B. Extra-osseous origin was diagnosed in 8/9 (89%) patients in group A and 8/13 (61%) patients in group B (P = 0.3). No significant differences between the two age groups regarding dose intensity, compliance with protocol, hematological and non-hematological toxicity, or overall survival were found. It was concluded that a multidisciplinary approach including multi-agent chemotherapy for a prolonged period of time is appropriate in adult patients with ESFT. Dose intensity of chemotherapy should be determined according to the patient's clinical status and comorbidities. Treatment protocols used in the pediatric population, including high-dose chemotherapy, should be adapted for the adult population.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Treatment of adult patients with Ewing’s sarcoma: compliance with chemotherapy protocols & toxicity

2010

View full text Add to dashboard Cite

show abstract

“…This retrospective series reveals a 79% LC rate in patients with nonmetastatic disease; intensive treatment resulted in infrequent but serious morbidity. With a 5-year CSS rate of only 44% for nonmetastatic disease and 34% for metastatic disease, the prognosis of these patients is poor compared with Ewing series addressing other sites, both from our institution and elsewhere (5,(11)(12)(13)(14)(15)(16)(17)(18).…”

Section: Discussionmentioning

confidence: 69%

Chest Wall Ewing Sarcoma Family of Tumors: Long-Term Outcomes

Indelicato¹,

Keole²,

Lagmay³

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

“…Radiotherapy may be used as the primary local control modality or combined with surgery. 89,90 Indications for radiotherapy include unplanned positive margins in resected tumors, unresectable tumors, tumors for which resection would cause unacceptable morbidity (e.g. acetabulum and spine) and in tumors that have poor chemotherapeutic response.…”

Section: Ewing Sarcomamentioning

confidence: 99%

Treatment of Bone Tumors

Rajani

Gibbs

2012

Surgical Pathology Clinics

View full text Add to dashboard Cite

Synopsis In this article, the authors summarize the state of the art and future potential in the management of Osteosarcoma, Ewing’s sarcoma, and Chondrosarcoma. They cover systemic therapy, surgical therapy, and radiotherapy, along with targeted therapies to inhibit signal transduction pathways. They discuss staging and the role of imaging evaluation to provide an overview of bone tumor treatment. Images presenting pathologic-radiologic correlations are included.

show abstract

Radiation Treatment for Ewing Family of Tumors in Adults: The University of Florida Experience

Cited by 15 publications

References 22 publications

Treatment of adult patients with Ewing’s sarcoma: compliance with chemotherapy protocols & toxicity

Treatment of adult patients with Ewing’s sarcoma: compliance with chemotherapy protocols & toxicity

Chest Wall Ewing Sarcoma Family of Tumors: Long-Term Outcomes

Treatment of Bone Tumors

Contact Info

Product

Resources

About